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Decrease in Core Temperature as an 
Indication of Cholinergic Overdrive during 
Amitriptyline Withdrawal 
Steven C. D&aver and Mark J. Majchrzak 
Introduction 
Dilsaver et al. (1983a,b, 1984) observed that 
the withdrawal of tricyclic antidepressants (TCAs) 
results in the development of an array of symp- 
toms that can be categorized to define four syn- 
dromes: (1) general somatic distress with flu- 
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like symptomatology, (2) excessive, vivid 
dreaming and initial, middle, and terminal in- 
somnia, (3) parkinsonism or akathisia, and 
(4) hypomania. The first three syndromes may 
be due to withdrawal-induced cholinergic ov- 
erdrive at peripheral and central sites. 
The hypothesis that TCA withdrawal pro- 
duces cholinergic overdrive is supported by re- 
ports that antimuscarinic agents produce toler- 
ance (Friedman et al. 1969), all TCAs block 
physiological (Dilsaver 1986) and biochemical 
responses mediated by muscarinic receptors 
(mAchRs) (Richelson and Dininetz-Romero 
1977), and TCAs competitively displace mAchR 
receptor radioantagonists in vitro (Snyder and 
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Yamamura 1977; Batra and Biorklund 1986). 
Finally, TCA withdrawal symptoms respond to 
centrally active antimuscarinic agents (Dilsaver 
et al. 1983a). 
Dilsaver et al. (1987) recently demonstrated 
that chronic treatment with amitriptyline hydro- 
chloride (AMI) results in supersensitivity to the 
hypothermic effects of the muscarinic agonist 
oxotremorine. The capacity of this TCA to pro- 
duce this effect demonstrates dose dependence 
(Dilsaver and Snider 1987). However, these 
pharmacological paradigms deviate from the 
clinical situation. In human subjects, the de- 
velopment of TCA withdrawal symptoms pre- 
sumably results in cholinergic rebound, the 
symptomatic effects of which are evident with- 
out the administration of a cholinomimetic agent. 
We recently conducted two experiments in which 
we treated rats with AMI, 10 mg/kg twice daily, 
for 7-2 1 days and then measured the fall in core 
temperature relative to baseline (prior to the first 
injection of AMI) 12 or 18 hr after the previous 
injection of AMI. 
Methods 
Experiment I 
Eight adult male Sprague-Dawley rats (11 weeks 
old) received AMI, 10 mg/kg ip, at 9:00 AM 
and 5:00 PM. Core temperature of each animal 
was telemetrically measured before and after 1 
and 3 weeks of treatment with AM1 using the 
Model VM Mini-Muter (Mini-Muter Corp., Sun 
River, OR). The second and third measurements 
were made 18 hr after the previous dose of AMI. 
Core temperature was measured 1 and 3 weeks 
after treatment. The reliability and validity of 
temperature measurements using this device was 
described elsewhere (Tocco-Bradley et al. 1985). 
Animals were injected with methylscopolamine 
nitrate, 1 mg/kg ip, 30 min prior to the mea- 
surement of core temperature to block peripheral 
cholinergic effects. 
Experiment 2 
Core temperature was measured in up to 12 adult 
male Sprague-Dawley rats (age circa 8 weeks) 
prior to and after 14, 15, and 16 days of treat- 
ment with AMI, 10 mg/kg at -12-hr intervals. 
Methylscopolamine nitrate, 1 mg/kg ip, was ad- 
ministered 30 min prior to the measurement of 
baseline temperature. Baseline temperature was 
measured once again after 17 days of treatment. 
However, this measurement was preceded by 
the administration of scopolamine hydrobrom- 
ide, 2.0 mg/kg ip. The actual number of animals 
yielding useful data varied due to occasional 
Mini-Mitter failure. Instrument failure is gen- 
erally the consequence of poor contact between 
a battery inside the device and a connecting 
wire. It is not uncommon for these two elements 
to spontaneously reunite and the instrument to 
begin transmitting. Thus, we have data on 10, 
12, 10, and 10 animals after 14, 15, 16, and 17 
days of treatment. 
Statistical Analysis 
Data were analyzed using EPISTAT, a statis- 
tical package, on an IBM PC. Significance was 
assessed using Student’s paired t-test. Measures 




Mean baseline core temperature prior to treat- 
ment with AM1 was 36.6 + 0.13”C versus 
36.0 + 0.27”C after 1 week (p < 0.001, 
t = 5.44, df = 7) and 35.8 + 0.25”C (p < 
0.035, t = 2.71, df = 7) after 3 weeks of 
treatment. 
Experiment 2 
Mean baseline temperature prior to treatment 
with AM1 was 36.8 2 0.05”C. After 14 days 
of treatment, mean baseline temperature was 
36.4 r O.l3”C@ < 0.006, t = 3.61, df = 9). 
Mean baseline temperature of those animals re- 
ceiving 15 and 16 days of treatment was 
36.4 ? 0.13”C @ < 0.006, t = 3.43, df = 11) 
and 36.4 + 0.19”C (p < 0.09, t = 1.88, 
df = lo), respectively. 
The mean baseline temperature of those an- 
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imals challenged with scopolamine at baseline 
was 36.7 2 0.07”C versus 36.7 f. 0.17”C af- 
terwards (NS, I = 0.00, df = 9). 
Discussion 
Core temperature was significantly decreased after 
7, 14, and 2 1 days in Experiment 1 and after 
15 days of treatment in Experiment 2. Further- 
more, the decrease in core temperature on day 
16 in Experiment 2 constituted a trend toward 
significance. The fact that pretreatment with 
scopolamine completely eliminated the differ- 
ence between the pretreatment and posttreat- 
ment baseline temperatures suggests that a 12- 
18 hr lapse between injections of AMI may pro- 
mote the development of a mild cholinergic 
overdrive state that is sufficient to produce a 
decrease in core temperature. 
The data suggest that a spontaneous reduction 
in core temperature provides an indication of 
AM1 withdrawal-induced cholinergic overdrive. 
The data are also consistent with the capacity 
of AM1 to supersensitize a central muscarinic 
mechanism (Dilsaver et al. 1987), and the as- 
sociation between its withdrawal and the oc- 
currence of symptoms is suggestive of cholin- 
ergic rebound (Dilsaver et al. 1983a,b; Dilsaver 
and Greden 1984). 
Our data raise the question of the effect of 
AMI on core temperature. Lee et al. (1977) 
studied the effect of a single injection of AMI 
on rectal temperature. Analysis disclosed a sig- 
nificant decrease lasting 3-4 hr for AMI, 20 and 
50 mg/kg, but not for 10 mg/kg. Pawlowski 
( 1983) observed that AMI, 10 mg/kg ip, did not 
alter basal temperature. Other reports of the ef- 
fect of AMI on core temperature relate to spe- 
cial circumstances or unusually high doses. In 
summary, there is evidence that doses of AM1 
much higher than 10 mg/kg lower core temper- 
ature. However, the dose employed in the ex- 
periments presented here is not known to de- 
crease core temperature. Thus, the effect re- 
ported here is most likely due to effects of drug 
withdrawal. 
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